Cefotaxime/sulbactam plus gentamicin as a potential carbapenem- and amikacin-sparing first-line combination for neonatal sepsis in high ESBL prevalence settings
John Readman(St George's, University of London), Joseph F. Standing(System Simulation (United Kingdom)), Adnan M. H. Hamawandi(St George's, University of London), Jodi A. Lindsay(Royal Veterinary College), Cheng-Hsun Chiu(Chang Gung University), Mike Sharland(St George's, University of London), Mislav Acman(University College London)
Cited by 7
Related Papers
Emergence of genomic diversity and recurrent mutations in SARS-CoV-2
|Infection Genetics and Evolution|2020|897
No evidence for increased transmissibility from recurrent mutations in SARS-CoV-2
|Nature Communications|2020|318
Role of mobile genetic elements in the global dissemination of the carbapenem resistance gene blaNDM
|Nature Communications|2022|247
Large-scale network analysis captures biological features of bacterial plasmids
|Nature Communications|2020|136
No evidence for increased transmissibility from recurrent mutations in SARS-CoV-2
|bioRxiv (Cold Spring Harbor Laboratory)|2020|92